2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Non-Small-Cell Lung
74
Breast Neoplasms
70
Rectal Neoplasms
51
Stomach Neoplasms
45
Glioblastoma
45
Esophageal Neoplasms
41
Colorectal Neoplasms
37
Lung Neoplasms
35
Brain Neoplasms
35
Squamous Cell Carcinoma of Head and Neck
32
Pancreatic Neoplasms
31
Glioma
27
Neoplasms
26
Sarcoma
24
Neoplasm Metastasis
23
Astrocytoma
22
Head and Neck Neoplasms
21
Carcinoma, Hepatocellular
19
Esophageal Squamous Cell Carcinoma
16
Colonic Neoplasms
16
Recurrence
15
Ovarian Neoplasms
15
Melanoma
15
Gliosarcoma
15
Central Nervous System Neoplasms
15
Urinary Bladder Neoplasms
13
Oligodendroglioma
13
Uterine Cervical Neoplasms
12
Adenocarcinoma Of Esophagus
12
Prostatic Neoplasms
11
Interventions
Ipilimumab
17
tremelimumab
9
Nivolumab
9
durvalumab
8
pembrolizumab
6
Paclitaxel
5
Carboplatin
4
Capecitabine
4
Bevacizumab
4
lenvatinib
3
spartalizumab
2
balstilimab
2
Radiotherapy
2
Radiation
2
Pemetrexed
2
Oxaliplatin
2
Doxorubicin
2
Docetaxel
2
Cisplatin
2
CTLA-4 Antigen
2
Blood Specimen Collection
2
trastuzumab deruxtecan
1
tilsotolimod
1
tebentafusp
1
relatlimab
1
poly ICLC
1
osimertinib
1
folfirinox
1
eribulin
1
envafolimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Surgical Procedures, Operative
×
Clear all
NCT03116529
2024-11-04
NEXIS
University of Maryland, Baltimore
Phase 1/2
Terminated
22 enrolled